Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel Meeting Abstract


Authors: Fizazi, K.; Scher, H. I.; Molina, A.; Logothetis, C. J.; Jones, R. J.; Staffurth, J. N.; Li, J.; Kheoh, T.; Haqq, C. M.; de Bono, J. S.
Abstract Title: Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel
Meeting Title: 16th ECCO - 36th ESMO - 30th ESTRO European Multidisciplinary Cancer Congress (EMCC 2011)
Journal Title: European Journal of Cancer
Volume: 47
Issue: Suppl. 1
Meeting Dates: 2011 Sep 23-27
Meeting Location: Stockholm, Sweden
ISSN: 0959-8049
Publisher: Elsevier Inc.  
Date Published: 2011-09-01
Start Page: S483
End Page: S484
Language: English
ACCESSION: WOS:000295752801677
PROVIDER: wos
DOI: 10.1016/S0959-8049(11)71951-7
Notes: Meeting Abstract: 7000 -- European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care - SEP 23-27, 2011 - Stockholm, SWEDEN - "Source: Wos"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1130 Scher